Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform

References

• Arai K, Kinumaki T, Fujita T. Toxicity of chitosan. Bull Tokai Feg Fish Res Lab 1968; 56: 89–95
   Google Scholar
• Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. Chitosan as a nasal delivery system: the effect of chitosan suspensions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509–513
   PubMed Web of Science ®Google Scholar
• Bagley KC, Abdelwahab SF, Tuskan RG, Lewis GK. An enzymatically active domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun 2003; 71: 6850–6856
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51: 717–722
   PubMed Web of Science ®Google Scholar
• Baudner BC, Balland O, Giuliani MM, Von Hoegen P, Rappuoli R, Betbeder D, Del Giudice G. Enhancement of protective efficacy following intranasal immunization with vaccine plus nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun 2002; 70: 4785–4790
   PubMed Web of Science ®Google Scholar
• Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Del Giudice G. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 2003; 21: 3837–3844
   PubMed Web of Science ®Google Scholar
• Baudner BC, Verhoef JC, Junginger HE, Del Giudice G. Mucosal adjuvants and delivery systems for oral and nasal vaccination. Drugs of the Future 2004; 29: 721–732
   Web of Science ®Google Scholar
• Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997; 14: 1431–1436
   PubMed Web of Science ®Google Scholar
• Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992; 10: 691–698
   PubMed Web of Science ®Google Scholar
• Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003; 42: 1107–1128
   PubMed Web of Science ®Google Scholar
• Debin A, Kravtzoff R, Santiago JV, Cazales L, Sperandio S, Melber K, Janowicz Z, Betbeder D, Moynier M. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 2002; 20: 2752–2763
   PubMed Web of Science ®Google Scholar
• Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, Smith A, Illum L. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 2002; 19: 998–1008
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20: 2431–2438
   PubMed Web of Science ®Google Scholar
• Gagliardi MC, Sallusto F, Marinaro M, Vendetti S, Riccomi A, De Magistris MT. Effects of the adjuvant cholera toxin on dendritic cells: Stimulatory and inhibitory signals that result in the amplification of immune responses. Int J Med Microbiol 2002; 291: 571–575
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187: 1123–1132
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to meningococcus. I. The role of human antibodies. J Exp Med 1969; 129: 1307–1326
   PubMed Web of Science ®Google Scholar
• Hirano S, Seino H, Akiyama Y, Nonaka I. Biocompatibility of chitosan by oral and intravenous administration. Polym Eng Sci 1989; 59: 897–901, 906
   Google Scholar
• Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001; 50: 107–142
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51: 81–96
   PubMed Web of Science ®Google Scholar
• Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS. Intranasal delivery of morphine. J Pharmacol Exp Ther 2002; 301: 391–400
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998; 16: 2039–2046
   PubMed Web of Science ®Google Scholar
• Janoff EN, Fasching C, Orenstein JM, Rubins JB, Opstad NL, Dalmasso AP. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Inves 1999; 104: 1139–1147
   PubMed Web of Science ®Google Scholar
• Kumar MN, Muzzarelli RA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004; 104: 6017–6084
   PubMed Web of Science ®Google Scholar
• Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of Chitosan and some other natural polymeres. Int J Pharm Sci 1992; 80: 43–48
   Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: Enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004; 22: 909–914
   PubMed Web of Science ®Google Scholar
• McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KH. A mucosal vaccine against diphtheria: Formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2000; 19: 1188–1198
   PubMed Web of Science ®Google Scholar
• Mills KH, Cosgrove C, McNeela EA, Sexton A, Giemza R, Jabbal-Gill I, Church A, Lin W, Illum L, Podda A, Rappuoli R, Pizza M, Griffin GE, Lewis DJ. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 2003; 71: 726–732
   PubMed Web of Science ®Google Scholar
• Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 2004; 4: 671–674
   Google Scholar
• Paul W, Sharma CP. Chitosan, a drug carrier for the 21st century: A review. STP Pharma Sci 2000; 10: 5–22
   Google Scholar
• Peppoloni S, Ruggiero P, Contorni M, Morandi M, Pizza M, Rappuoli R, Podda A, Del Giudice G. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003; 2: 285–293
   PubMedGoogle Scholar
• Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, Chain BM. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 2003; 21: 1445–1454
   PubMed Web of Science ®Google Scholar
• Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G. Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19: 2534–2541
   PubMed Web of Science ®Google Scholar
• Roos A, Bouwman LH, Van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861–2868
   PubMed Web of Science ®Google Scholar
• Seferian PG, Martinez ML. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000; 19: 661–668
   PubMed Web of Science ®Google Scholar
• Sieval AB, Thanou M, Kotzé AF, Verhoef JC, Brussee J, Junginger HE. Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydr Polym 1998; 36: 157–165
   Web of Science ®Google Scholar
• Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 2001; 70: 267–276
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000; 97: 811–816
   PubMed Web of Science ®Google Scholar
• Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999; 178: 55–65
   PubMed Web of Science ®Google Scholar
• Thanou MM, Kotzé AF, Scharringhausen T, Lueßen HL, De Boer AG, Verhoef JC, Junginger HE. Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers. J Control Release 2000; 64: 15–25
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 2001; 52: 117–126
   PubMed Web of Science ®Google Scholar
• VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 1998; 160: 2000–2012
   PubMed Web of Science ®Google Scholar
• Van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice. Vaccine 2003; 21: 1400–1408
   PubMed Web of Science ®Google Scholar
• Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001; 52: 139–144
   PubMed Web of Science ®Google Scholar
• Van der Lubben IM, Verhoef JC, Fretz MM, Van Opdorp FAC, Mesu I, Kersten G, Junginger HE. Trimethyl chitosan chloride (TMC) as a novel excipient for oral and nasal immunization against diphtheria. STP Pharma Sci 2002; 12: 235–242
   Google Scholar
• Van der Lubben IM, Verhoef JC, Van Aelst AC, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: Preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001; 22: 687–694
   PubMed Web of Science ®Google Scholar
• Van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165: 4778–4782
   PubMed Web of Science ®Google Scholar
• Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila Jato JL, Alonso MJ. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004; 57: 123–131
   PubMed Web of Science ®Google Scholar
• Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res 1997; 16: 187–201
   PubMed Web of Science ®Google Scholar